Test whether under GSK3 genetic LOF or matched GSK3-inhibitor condition that abolishes GSK3-class longevity attribution, lithium still retains lifespan phenotype on the same panel

Lithium longevity and healthspan benefits are often read as GSK3-necessary because McColl shows GSK-3β is essential for Li+ C. elegans lifespan extension and Castillo-Quan shows sgg RNAi epistatic with Li+ in Drosophila. This discussion asks whether, once GSK3 genetic LOF or matched GSK3-inhibitor abolishes GSK3-class longevity attribution, lithium still retains lifespan phenotype on the same C. elegans panel — without inventing residual-positive outcomes.

Claim

On a pre-registered C. elegans panel with lithium vs vehicle under GSK-3β/gsk-3 genetic LOF (or matched GSK3-inhibitor at a lock that abolishes GSK3-class longevity attribution) vs GSK3-intact concurrent controls, locking GSK3-class control benefit abolished under the block arm (primary referee = median lifespan; optional co-readouts = healthspan / locomotion only as secondary, not gate): under that block lock, same-panel median lifespan improvement (lithium vs vehicle under block) retains ≥50% of the lithium vs vehicle median lifespan improvement on GSK3-intact concurrent controls on the same panel (named comparator = lithium vs vehicle median lifespan Δ on GSK3-intact arm; units days as pre-specified; α/N pre-specified) — assumption-kill / gsk3-insufficiency of “lithium lifespan/healthspan = mere GSK3-necessary bridge with possible residual.” Residual-positive lifespan or healthspan H2H under GSK3 abolish = UNKNOWN (do not invent residual).

Why it matters

Lithium longevity and healthspan benefits are often framed as GSK3-necessary because McColl shows GSK-3β essential for Li+ C. elegans lifespan extension (gsk-3β null — no Li+ extension) and Castillo-Quan shows sgg RNAi epistatic with Li+ in Drosophila, yet a matched residual-positive H2H under GSK3 genetic LOF or matched GSK3-inhibitor that abolishes GSK3-class control remains untested as residual-positive (necessity prior art constrains residual; mouse residual under systemic GSK3 LOF UNKNOWN). L23 asks whether, once GSK3 genetic LOF or matched GSK3-inhibitor abolishes GSK3-class longevity attribution, lithium still retains lifespan phenotype on the same panel — lifespan ≠ mere GSK3-sole-necessity bridge with invented residual. Distinct from L15 (DunedinPACE-without-GrimAge × Oh organ-age), L16 (tissue SA-β-gal/p16 vs blood under D+Q), L17 (intermittent-rapa FKBP-high tissue mTORC2), L18 (17α-E2 × caloric-match residual), L19 (acarbose × glycemic-match residual), L20 (SPD residual under ATG5/7 / autophagy-insufficiency — GSK3 ≠ bulk ATG), L21 (UA residual under PINK1/Parkin / mitophagy-insufficiency — GSK3 ≠ mitophagy), and L22 (metformin residual under AMPK LOF/Compound C / ampk-insufficiency — GSK3 ≠ AMPK); NOT NAD-after-senolysis. Soft-claims: discussion — residual-positive lithium lifespan/healthspan under GSK3 abolish UNKNOWN; PRIOR_ART PARTIAL (necessity against residual C. elegans and Drosophila lifespan; residual-positive H2H absent; Zarse/Nespital phenotype priors without abolish arm); soft-complete empty ≠ novelty / ≠ failure; L1–L22 ≠ proof.

Mechanism sketch

gsk3-insufficiency assumption-kill: McColl J Biol Chem shows GSK-3β essential for Li+ C. elegans lifespan (necessity, inverse of residual; gsk-3β(nr2047) — Li+ does not extend; slight further decrease); Castillo-Quan Cell Rep shows Li+ Drosophila longevity via GSK3/NRF2 with sgg RNAi epistasis/saturation (Li+ unable to further extend sgg-RNAi lifespan); Zarse grounds human/metazoan low-dose Li longevity phenotype without GSK3-abolish residual arm; Nespital grounds mouse mild healthspan-not-lifespan phenotype without GSK3-abolish residual arm. Prefer C. elegans lifespan proxy ± lithium ± gsk-3/GSK-3β LOF (or matched GSK3-inhibitor that abolishes GSK3-class control) before new rodent or human dosing language; optional Drosophila long arm using Castillo-Quan-class lock; mouse residual under systemic GSK3 LOF only optional long arm; do not invent residual. Competing caveats: block not actually abolishing GSK3-class control benefit / underpowered strata / referee-assay mismatch leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ failure; L15 ≠ this; L16 ≠ this; L17 ≠ this; L18 ≠ this; L19 ≠ this; L20 ≠ this (GSK3 ≠ bulk ATG); L21 ≠ this (GSK3 ≠ mitophagy); L22 ≠ this (GSK3 ≠ AMPK). NOT NAD-after-senolysis (SERIES_FROZEN). Do not invent residual effect sizes.

Prior art

• PMID 17959600 / DOI 10.1074/jbc.M705028200 / PMC2739662 — McColl: Li+ throughout adulthood extends C. elegans survival (up to ~46% median); gsk-3β(nr2047) shortens median lifespan; Li+ does not extend gsk-3β null (slight further decrease) — lifespan extension by Li+ requires GSK-3β — NECESSITY (inverse of residual) against residual lifespan claim; not residual-positive H2H under GSK3 abolish.
• PMID 27068460 / DOI 10.1016/j.celrep.2016.03.041 / PMC4850359 — Castillo-Quan: Li+ extends Drosophila lifespan via GSK-3 inhibition and NRF-2/CncC activation; sgg RNAi extends lifespan and Li+ unable to further increase sgg-RNAi lifespan; lithium and Sgg inhibition epistatic/common pathway — NECESSITY/saturation against residual-positive under GSK3 abolish.
• PMID 21301855 / DOI 10.1007/s00394-011-0171-x / PMC3151375 — Zarse: inverse correlation tap-water Li vs all-cause mortality (Japanese municipalities); low-dose LiCl extends C. elegans lifespan — phenotype prior; no GSK3 genetic LOF or matched GSK3-inhibitor residual lifespan H2H on same panel.
• PMID 34532960 / DOI 10.1111/acel.13479 / PMC8520709 — Nespital: Li within tolerable range mildly increases mouse healthspan but not lifespan — phenotype prior; no GSK3 genetic or inhibitor residual arm on same panel.

Baseline claimed

Under GSK3 genetic LOF or matched GSK3-inhibitor condition that abolishes GSK3-class longevity attribution, lithium still retains lifespan or healthspan phenotype on the same panel — or McColl 2008 residual under gsk-3 open / Castillo-Quan 2016 sgg RNAi proves residual under GSK3 abolish / Zarse/Tam/Nespital settle residual under GSK3 LOF / L15 Oh organ-age / L16 tissue-vs-blood under D+Q / L17 intermittent-rapa FKBP / L18 17α-E2 caloric-match / L19 acarbose glycemic-match / L20 SPD/ATG bulk autophagy / L21 UA/mitophagy / L22 metformin/AMPK / L1–L22 already settle the residual H2H.

Baseline measured

McColl NECESSITY lifespan LITERATURE against residual (PMID 17959600). Castillo-Quan NECESSITY/saturation lifespan LITERATURE against residual (PMID 27068460). Zarse human/metazoan low-dose Li LITERATURE phenotype prior without GSK3-abolish residual arm (PMID 21301855). Nespital mouse healthspan-not-lifespan LITERATURE phenotype prior without GSK3-abolish residual arm (PMID 34532960). Residual-positive lithium lifespan or healthspan H2H under GSK3 genetic LOF or matched GSK3-inhibitor that abolishes GSK3-class control UNKNOWN (soft-complete Q_resid/Q_resid2 = necessity+NON-MATCH; no residual-positive; mouse residual under systemic GSK3 LOF UNKNOWN). Block-arm median lifespan improvement retains ≥50% of GSK3-intact lithium vs vehicle median lifespan improvement PREDICTION. L15 ≠ L23; L16 ≠ L23; L17 ≠ L23; L18 ≠ L23; L19 ≠ L23; L20 ≠ L23 (GSK3 ≠ bulk ATG); L21 ≠ L23 (GSK3 ≠ mitophagy); L22 ≠ L23 (GSK3 ≠ AMPK); L1–L22 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT NAD-after-senolysis. Do not invent residual.

Actionable limitations

1. Do not treat L1–L22 as proving L23 — new parent area lithium-gsk3-insufficiency; McColl/Castillo-Quan/Zarse/Nespital layers are necessity or phenotype adjacent, not residual-positive H2H under GSK3 abolish; soft-complete empty ≠ demonstrated prediction-failure; do not invent residual.
2. 17959600 NECESSITY constrains residual C. elegans lifespan; 27068460 NECESSITY/saturation constrains residual Drosophila lifespan; 21301855 / 34532960 lack GSK3-abolish residual arm — matched residual-positive lifespan/healthspan H2H UNKNOWN — PRIOR_ART PARTIAL.
3. L15 ≠ L23; L16 ≠ L23; L17 ≠ L23; L18 ≠ L23; L19 ≠ L23; L20 ≠ L23 (GSK3 ≠ bulk ATG); L21 ≠ L23 (GSK3 ≠ mitophagy); L22 ≠ L23 (GSK3 ≠ AMPK); NAD/CD38 soft-complete NON-MATCH — NOT SERIES_FROZEN NAD-after-senolysis; reviews ≠ anchors; no dosing; ip_class ≠ none.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion

Prediction variables

Ablate

• remove matched lithium ± gsk-3/GSK-3β LOF (or matched GSK3-inhibitor abolishing GSK3-class control) vs GSK3-intact concurrent controls with same-panel median lifespan residual co-readout: Without the block-lock × residual lifespan H2H on the same panel, separate McColl/Castillo-Quan necessity LITERATURE and Zarse/Nespital phenotype priors cannot show lifespan ≠ mere GSK3-sole-necessity bridge, and residual-positive stays untested (not invented).
• remove block-arm median lifespan improvement scored against the GSK3-intact lithium vs vehicle median lifespan improvement as named comparator under the abolished-control lock (vs necessity-alone): Without the intact-arm lithium vs vehicle median lifespan comparator under the block lock, the card collapses into unmatched necessity framing and loses the gsk3-insufficiency assumption-kill.
• remove L15≠L23 + L16≠L23 + L17≠L23 + L18≠L23 + L19≠L23 + L20≠L23 + L21≠L23 + L22≠L23 + L1–L22≠proof + soft-complete-empty≠novelty + residual-UNKNOWN + GSK3≠bulk-ATG + GSK3≠mitophagy + GSK3≠AMPK + NOT-NAD-after-senolysis discipline: Treating L15 Oh organ-age, L16 tissue-vs-blood, L17 intermittent-rapa FKBP, L18 caloric-match, L19 glycemic-match, L20 SPD/ATG bulk autophagy, L21 UA/mitophagy, L22 metformin/AMPK, empty PubMed, or NAD/CD38 adjacent hits as already deciding residual-positive under GSK3 abolish — or inventing residual effect sizes — would invent a result left UNKNOWN.

Refute if

On the pre-registered C. elegans panel where gsk-3/GSK-3β genetic LOF or matched GSK3-inhibitor locks GSK3-class control benefit abolished, same-panel median lifespan improvement (lithium vs vehicle under block) is <50% of the lithium vs vehicle median lifespan improvement on GSK3-intact concurrent controls — so lithium lifespan DOES reduce to mere GSK3-necessary bridge under abolished GSK3-class control and the gsk3-insufficiency assumption-kill fails — when block-not-abolished, underpowered-strata, or assay-mismatch artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one C. elegans lithium vs vehicle × gsk-3/GSK-3β genetic LOF (or matched GSK3-inhibitor) regimen with abolished GSK3-class-control-benefit definition, primary median lifespan (days) referee, optional healthspan/locomotion co-readout, and ≥50%-of-intact-lithium-vs-vehicle median lifespan retention gate before claiming residual under GSK3 abolish; prefer worm lifespan proxy before new rodent/human; do not invent residual; do not treat McColl necessity or Castillo-Quan epistasis or Zarse/Nespital phenotype or L15 or L16 or L17 or L18 or L19 or L20 or L21 or L22 or L1–L22 as residual-positive proof; GSK3 ≠ bulk ATG; GSK3 ≠ mitophagy; GSK3 ≠ AMPK; NOT NAD-after-senolysis; no dosing.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=gsk3-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=McColl 2008 lithium C. elegans GSK-3β necessity + Castillo-Quan 2016 Drosophila GSK3/NRF2 epistasis + Zarse 2011 human/metazoan low-dose Li + Nespital 2021 mouse healthspan-not-lifespan; L15 (Oh organ-age ≠ this); L16 (tissue-vs-blood under D+Q ≠ this); L17 (intermittent-rapa FKBP ≠ this); L18 (17α-E2 caloric-match ≠ this); L19 (acarbose glycemic-match ≠ this); L20 (SPD/ATG bulk autophagy ≠ this; GSK3 ≠ bulk ATG); L21 (UA/mitophagy ≠ this; GSK3 ≠ mitophagy); L22 (metformin/AMPK ≠ this; GSK3 ≠ AMPK); L1–L22 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: biology-life-sciences tags: aging, longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/L23.card.md card_sha256: 4e5e968091273e4633228965d0af6f5ce856be25a923df0f927eccc9a79bebe3

Mol Labs public report: PENDING dual-publish